Petros Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Petros Pharmaceuticals, Inc. (PTPI) reported Increase (Decrease) in Accounts Payable of $13.40 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$36.02K, a 108.63% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $49.42K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$337.26K, a 180.37% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$548.88K, a 480.72% decline year-over-year.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$680.45K, a 293.44% decline from fiscal 2024.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was $351.76K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2023 was -$93.15K.
- Petros Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$2.75M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 3 month as first filed | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 9 month as first filed | Increase (Decrease) in Accounts Payable 12 month | Increase (Decrease) in Accounts Payable 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$36.02K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.40K 10-Q · filed 2026-08-13 | -$323.86K derived: sum of 3 quarters · filed 2026-08-13 | -$872.74K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $49.42K 10-Q · filed 2026-05-13 | -$287.84K derived: sum of 2 quarters · filed 2026-05-13 | -$836.72K derived: sum of 3 quarters · filed 2026-05-13 | -$419.42K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$337.26K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$886.14K derived: sum of 2 quarters · filed 2026-04-15 | -$468.84K derived: sum of 3 quarters · filed 2026-08-13 | -$680.45K 10-K · filed 2026-04-15 | ||||
| 2025-09-30 | -$548.88K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$131.58K derived: sum of 2 quarters · filed 2026-08-13 | -$343.19K 10-Q · filed 2025-11-13 | $76.45K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $417.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $205.69K 10-Q · filed 2026-08-13 | $625.33K derived: sum of 3 quarters · filed 2026-08-13 | $769.50K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$211.61K 10-Q · filed 2026-05-13 | $208.03K derived: sum of 2 quarters · filed 2026-05-13 | $352.20K derived: sum of 3 quarters · filed 2026-05-13 | $188.20K derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $419.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $563.81K derived: sum of 2 quarters · filed 2026-04-15 | $399.81K derived: sum of 3 quarters · filed 2026-04-15 | $351.76K 10-K · filed 2026-04-15 | $615.68K 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $144.17K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$19.83K derived: sum of 2 quarters · filed 2025-11-13 | -$67.89K 10-Q · filed 2025-11-13 | -$112.29K 10-Q · filed 2024-11-13 | $290.30K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | -$164.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$212.06K 10-Q · filed 2025-08-14 | -$922.16K 10-Q · filed 2024-08-14 | $146.13K derived: sum of 3 quarters · filed 2025-08-14 | -$282.54K derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | -$48.06K 10-Q · filed 2025-05-15 | $424.00K 10-Q · filed 2024-05-15 | $310.13K derived: sum of 2 quarters · filed 2025-05-15 | -$118.54K derived: sum of 3 quarters · filed 2025-05-15 | -$193.16K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $358.19K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$70.48K derived: sum of 2 quarters · filed 2025-03-31 | -$145.10K derived: sum of 3 quarters · filed 2025-03-31 | -$93.15K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$428.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$503.29K derived: sum of 2 quarters · filed 2024-11-13 | -$451.34K 10-Q · filed 2024-11-13 | -$729.46K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$74.62K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$22.67K 10-Q · filed 2024-08-14 | -$300.79K derived: sum of 3 quarters · filed 2024-08-14 | -$120.82K derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $51.95K 10-Q · filed 2024-05-15 | -$226.17K derived: sum of 2 quarters · filed 2024-05-15 | -$46.20K derived: sum of 3 quarters · filed 2024-05-15 | -$1.84M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$278.12K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$98.15K derived: sum of 2 quarters · filed 2024-04-01 | -$1.89M derived: sum of 3 quarters · filed 2024-04-01 | -$2.75M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $179.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-15 | -$1.62M derived: sum of 2 quarters · filed 2023-11-15 | -$2.47M 10-Q · filed 2023-11-15 | -$3.23M derived: sum of 4 quarters · filed 2023-11-15 | ||||
| 2022-06-30 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$2.65M 10-Q · filed 2023-08-14 | -$3.41M derived: sum of 3 quarters · filed 2023-08-14 | -$693.34K derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | -$857.64K 10-Q · filed 2023-05-15 | -$1.61M derived: sum of 2 quarters · filed 2023-05-15 | $1.10M derived: sum of 3 quarters · filed 2023-05-15 | -$1.58M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$754.38K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-31 | $1.96M derived: sum of 2 quarters · filed 2023-03-31 | -$718.31K derived: sum of 3 quarters · filed 2023-03-31 | -$1.05M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $2.71M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-15 | $36.06K derived: sum of 2 quarters · filed 2022-11-15 | -$297.21K 10-Q/A · filed 2022-11-15 | -$2.60M derived: sum of 4 quarters · filed 2022-11-15 | ||||
| 2021-06-30 | -$2.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$3.01M 10-Q · filed 2022-08-12 | -$5.32M derived: sum of 3 quarters · filed 2022-08-12 | -$2.71M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | -$333.27K 10-Q · filed 2022-05-16 | -$2.64M derived: sum of 2 quarters · filed 2022-05-16 | -$32.41K derived: sum of 3 quarters · filed 2022-05-16 | $538.12K derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | -$2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $300.86K derived: sum of 2 quarters · filed 2022-03-31 | $871.39K derived: sum of 3 quarters · filed 2022-03-31 | $2.22M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.18M derived: sum of 2 quarters · filed 2021-11-15 | $4.53M 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $570.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $1.92M 10-Q · filed 2021-08-16 | ||||||
| 2020-03-31 | $1.35M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |